Recombinant Human CEACAM7/CGM2 Protein (His Tag) | PKSH032238

(No reviews yet) Write a Review
SKU:
575-PKSH032238
Weight:
1.00 KGS
€611.00
Frequently bought together:

Description

Recombinant Human CEACAM7/CGM2 Protein (His Tag) | PKSH032238 | Gentaur US, UK & Europe Disrtribition

Synonyms: Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7; Carcinoembryonic Antigen CGM2; CEACAM7; CGM2

Active Protein: N/A

Activity: Recombinant Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7 is produced by our Mammalian expression system and the target gene encoding Thr36-Phe142 is expressed with a 6His tag at the C-terminus.

Protein Construction: Recombinant Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7 is produced by our Mammalian expression system and the target gene encoding Thr36-Phe142 is expressed with a 6His tag at the C-terminus.

Fusion Tag: C-6His

Species: Human

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 13.1 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7 (CEACAM7) is a member of the immunoglobulin superfamily A and CEA family. CEACAM7 localizes to the cell membrane and contains one Ig-like C2-type domain and one Ig-like V-type domain. The expression of CEACAM7 is significantly decreased in rectal cancer. Differences in CEACAM7 expression levels between long-term survivors and those with recurrent disease introduce a potential tumor marker to define a subset of patients who benefit most from adjuvant therapy.

Research Area: Tags & Cell Markers

View AllClose